ClinicalTrials.gg
CompletedNCT01536379Updated Apr 25, 2017Results posted

A Study of Belimumab in the Prevention of Kidney Transplant Rejection

A Phase 2 interventional study of Belimumab and Placebo in Transplantation, Organ, sponsored by GlaxoSmithKline. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-04-25.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Kidney transplantation is the best treatment for many patients with kidney failure. Sometimes a transplanted kidney is rejected by the patient's immune system. Many types of immune system cells, including B cells, are active in rejection. B cells produce antibodies against anything the body sees as non-self, like germs or a transplanted kidney. Most medicines that help prevent transplant rejection affect cells other than B cells. Belimumab is a medication used to treat a disease called lupus. Belimumab slows development of antibody-producing B cells. This study will test whether belimumab works on parts of the immune system that cause rejection. Twenty to thirty adults getting a kidney transplant will be in this study. Like flipping a coin, a computer will randomly assign half to be given belimumab and half to be given placebo (a fake medicine). Patients and doctors will not know which medicine was assigned until the study is over. A total of 7 doses of study medicine will be given through a vein. One dose will be given during transplant surgery, and the other 6 will be given 2, 4, 8, 12, 16 and 20 weeks after transplant surgery. Usual transplant medicines will also be given. After all of the doses have been given, patients will be watched and tested at 24, 36, and 52 weeks after the transplant surgery. Blood samples will be tested to see what study medicines do to the immune system in transplant patients. If patients get a kidney biopsy, the samples will be tested to see if belimumab had any effect. Patients will be asked many questions to see if they are having any side effects. The study will be done at Addenbrooke's Hospital in Cambridge and Guys \&St Thomas Hospital in London, United Kingdom. A pharmaceutical company, GlaxoSmithKline, is funding the study.

02

Conditions studied

  • Transplantation, Organ

Browse trials for

Keywords

  • Infection
  • Quality of Life
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 30 is below the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible for kidney transplantation: Considered eligible for transplantation after undergoing multidisciplinary evaluation at the institution at which the transplantation will be performed
  • Donor characteristics: Receiving a deceased donor kidney or a living donor kidney allograft
  • Age \& Gender: Male or female between 18 and 75 years of age, inclusive, at the time of signing the
  • Female Subjects: Not pregnant or nursing and at least one of the following conditions apply: a. Non- defined as pre-menopausal females with a documented tubal ligation or hysterectomy or defined as 12 months of spontaneous amenorrhea. In the absence of confirmatory laboratory assessments [(a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 million international units per milliliter (MIU/mL) and estradiol \< 40 picogram per milliliter (pg/mL) (\<147 picomole per liter [pmol/L])] in questionable cases, female subjects will be required to use one of the methods as described by the investigator or designee, until confirmatory results become available; b. Questionable post-menopausal status and agrees to use one of the contraception methods as described by the investigator or designee, from Day 0 until 16 weeks after the last dose of product or until postmenopausal status is confirmed with a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MIU/mL and estradiol status who are using hormone replacement therapy (HRT) will be required to use one of the contraception methods as described by the investigator or designee, until post-menopausal status is confirmed. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method; c. Child-bearing potential and agrees to use one of the contraception methods as described by the investigator or designee, from Day 0 until 16 weeks after the last dose of investigational product.
  • Liver function (most recent values available before transplantation): (ALT) \< 2x (ULN); \<= 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • : at the time of transplantation, planned to receive a combination of immunosuppressants including basiliximab, mycophenolate mofetil, tacrolimus, prednisolone

Exclusion criteria

Exclusion Criteria:

  • Donor characteristics: receiving a kidney allograft from a donor with any of the following characteristics: a) cold ischemic time exceeding 36 hours; b) age \< 5 years old; c) for donors after brain death (DBD), age >70 years old; d) for donors after cardiac death (DCD) age >70 years old; e) ABO blood type incompatible against the recipient; f) 0 0 0 HLA-A -B -DR mismatch against the recipient by National Health Service Blood and Transplant (NHSBT criteria; g) T- and/or B-cell positive crossmatch by complement dependent cytotoxicity or flow cytometry against the recipient. Note :- (In some situations it may be that a pre-existing T- and/or B-cell positive crossmatch by complement dependent cytotoxicity or flow cytometry against the recipient will only be fully revealed immediately after the transplant; in such situations they will be recorded as having met exclusion criteria and withdraw from further involvement in the study; h) serology positive for (except hepatitis B surface antibody and prior vaccination), or (HIV)
  • Transplant other than kidney: has previously received a hematopoietic stem cell/marrow transplant or an organ transplant other than a kidney (with the exception of corneal transplantation)
  • Planned regimen: are being considered for -free or alemtuzumab induction
  • Prior therapy at any time: has ever received any of the following: a) B-cell targeted therapy (e.g., rituximab, other anti-CD20 agents, anti-CD22 [epratuzumab], anti-CD52 [alemtuzumab], BLyS-receptor fusion protein [BR3], TACI fragment, crystallizable (Fc), or belimumab)
  • 364 Day prior therapy: has received any of the following within 364 days before Day 0: a) Cyclophosphamide; b) Abatacept; c) A biologic agent other than B-cell targeted therapy [e.g., abetimus sodium, anti 0L antibody (e.g., BG9588/ IDEC 131; investigational agent applies to any drug not approved for sale in the country in which it is being used]
  • 90 Day prior therapy: has received any of the following within 90 days before Day 0: a) Anti- Tumor necrosis factor (TNF) or anti-Interleukin (IL)-6 therapy (e.g., adalimumab, etanercept, infliximab, tocilizumab); b) Interleukin-1 receptor antagonists (e.g., anakinra); c) Intravenous immunoglobulin (IVIG); d) Plasmapheresis, leukapheresis
  • 60 Day prior therapy: has received any of the following within 60 days before Day 0: a) A non-biologic investigational agent (investigational agent applies to any drug not approved for sale in the country in which it is being used); b) Any new immunosuppressive/immunomodulatory agent; tacrolimus, Mycophenolate mofetil (MMF), and corticosteroids are permitted. Inhaled steroids and new topical immunosuppressive agents (e.g., eye drops, topical creams) are also allowed.
  • 30 Day prior therapy: has received any of the following within 30 days before Day 0: a) A ; b) An increase in dose of an immunosuppressive/immunomodulatory agent (decreases in dose or discontinuations are permitted). Increases in doses of tacrolimus, MMF, and corticosteroids are permitted.
  • : has a history of malignancy in the past 5 years except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix.
  • Acute or chronic infection: has required management of acute or chronic infections (excludes prophylaxis of infections), as follows: a) Currently receiving any suppressive therapy for a chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria), which, in the opinion of the investigator, could put the subject at undue risk; b) Hospitalized for treatment of infection within 30 days before Day 0, which, in the opinion of the investigator, could put the subject at undue risk ; c) Treated for an infection with parenteral (intravenous or intramuscular)] antibiotics (antibacterials, antivirals, anti-fungals, or anti-parasitic agents) within 30 days before Day 0, which, in the opinion of the investigator, could put the subject at undue risk
  • Other disease/conditions: has any of the following: a) clinical evidence of significant unstable or uncontrolled acute or chronic diseases (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, neurological, malignancy or infectious diseases) which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk; b) a surgical procedure planned in the 6 months after Day 0, other than kidney transplantation or related procedure; c) a known history of any other medical disease (e.g., cardiopulmonary), laboratory abnormality, or condition (e.g., poor venous access) that, in the opinion of the investigator, makes the subject unsuitable for the study
  • Hepatitis: known to have serologic evidence of hepatitis B infection based on the results of testing for hepatitis B surface antigen (HBsAg), or antibodies against hepatitis B core antigen (HBc) and/or hepatitis B surface antigen (HBs) as follows: a) Patients positive for HBsAg are excluded; ) Patients negative for HBsAg and anti-HBc antibody but positive for anti-HBs antibody and with no history of hepatitis B vaccination are excluded; c) Patients negative for HBsAg but positive for both anti-HBc and anti-HBs antibodies are excluded; d) Patients negative for HBsAg and anti-HBs antibody but positive for anti-HBc antibody are excluded; e) Or has known serologic evidence of hepatitis C infection based on the results of testing for hepatitis C antibody and hepatitis C recombinant immunoblot assay (RIBA) as follows: Patients with a positive test for Hepatitis C antibody confirmed on the same sample with a Hepatitis C RIBA immunoblot assay. Patients who are positive for Hepatitis C antibody, and who are negative when the Hepatitis C RIBA immunoblot assay is performed on the same sample, will be eligible to participate. Patients who are positive for Hepatitis C antibody and who have a positive or indeterminate result when the Hepatitis C RIBA immunoblot assay is performed on the same sample, will not be eligible to participate.
  • HIV: known to have a historically positive HIV test or tests positive at screening for HIV.
  • Immunodeficiency: recipient with a history of immunodeficiency (defined as Immunoglobulin A isotype (IgA) level \<10 milligrams per deciliter (mg/dL) or have Immunoglobulin G isotype (IgG) level \<400 mg/dL).
  • Laboratory abnormalities: has an abnormal laboratory assessment, which is judged by the investigator.
  • Lymphopenia: has a lymphocyte count \<500/ millimeter (mm)\^3.
  • Drug Sensitivity: has a history of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy including a previous anaphylactic reaction to parenteral administration contrast agents, human or murine proteins or monoclonal antibodies that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
  • Substance abuse: has evidence of current drug or alcohol abuse or dependence.
  • Blood donation: where participation in the study would result in donation of blood or blood products in excess of 700 mL within a 56-day period
  • Venous access: has venous access limitations likely to preclude monthly infusions
  • Compliance: is unlikely to comply with scheduled study visits based on investigator judgment or has a history of substance abuse, psychiatric disorder or condition that may compromise communication with the investigator
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Belimumab 10 mg

    Subjects will receive belimumab 10 mg/ Kilogram (kg) infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care.

    Drug: Belimumab

  • Placebo comparator
    Placebo

    Subjects will receive placebo infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care

    Drug: Placebo

Interventions

  • Belimumab (10 mg/kg) will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)

  • DrugPlacebo

    Placebo will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in naïve B Cells From Baseline to Week 24

    Naive B cell is cell that is not exposed to antigen. Naïve B cell count is CD20+CD27 concentration of cells (conc-cell)/cubic millimeter (cumm). Change from Baseline in naïve B cells was calculated as the value at Week 24 minus the value at Baseline. MITT Population consisted of all participants randomized to treatment, who have had taken at least one dose of study. Participants analyzed included those who had data at Week 24 for naïve B cells count (MITT Population). Baseline value used in the analysis was of Day 0 (Day of transplant). Adjusted mean differences (treatment-placebo) and 95% confidence intervals for differences were obtained from mixed-models repeated-measures (MMRM) model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments.

    Time frame: Baseline and Week 24

  2. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)

    Number of participants with AEs, SAEs and AESI are summarized. The On-treatment (OT) phase started on the day and time of receiving the start of the first infusion and ended on the last dose date plus 28 days. The Post-treatment (PT) phase started 29 days after day of last dose up to 1 year. An AE is any untoward medical occurrence, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that at any dose results in, death, is life threatening, Requires hospitalization or prolongation of existing hospitalization, Results in disability/incapacity, Is a congenital anomaly/birth defect or event that but may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed. AESI included malignant neoplasms, infusion/anaphylaxis/hypersensitivity reactions, all infections, depression/suicide/self-injury, deaths.

    Time frame: Up to 1 year

  3. Number of Incidence of All Infections and Serious Infections

    All infections included: 1. Opportunistic infections per-clinical assessment, 2. Herpes Zoster, a. Recurrent, b. Disseminated, 3. Sepsis. Opportunistic infections were identified using list of preferred terms as per Medical Dictionary for Regulatory Activities (MedDRA) version 18.1. Any events falling under these preferred terms were adjudicated to determine if criteria was met for an opportunistic infection.

    Time frame: Up to 1 year

  4. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 24 and Week 52

    Change from Baseline in SBP and DBP were assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value at Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24 and Week 52

  5. Change From Baseline in Heart Rate From Baseline at Week 24 and Week 52

    Change from Baseline in heart rate was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value at Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24 and Week 52

  6. Change From Baseline in Body Temperature From Baseline at Week 24 and Week 52

    Change from Baseline in body temperature was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value at Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24 and Week 52

  7. Number of Participants Outside the Normal Range (NR) for SBP and DBP at Week 24 and Week 52

    Number of participants outside the normal range (NR) for SBP and DBP was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Number of participants outside the normal range are summarized by less than (\<) normal range and greater than (\>) normal range categories at Week 24 and Week 52. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Week 24 and Week 52

  8. Number of Participants Outside the Normal Range (NR) for Heart Rate at Week 24 and Week 52

    Number of participants outside the normal range (NR) for heart rate was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Number of participants outside the normal range are summarized by less than (\<) normal range and greater than (\>) normal range categories at Week 24 and Week 52. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Week 24 and Week 52

  9. Number of Participants Outside the Normal Range (NR) for Body Temperature at Week 24 and Week 52

    Number of participants outside the normal range (NR) for body temperature was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Number of participants outside the normal range are summarized by less than (\<) normal range and greater than (\>) normal range categories at Week 24 and Week 52. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Week 24 and Week 52

  10. Change From Baseline in the Indicated Hematology Parameters at Week 24 and Week 52

    Hematology parameters included: basophils (B), eosinophils (E), lymphocytes (L), monocytes (M), total neutrophils (N), platelet count (PC) and white blood cells (WBC). Change from Baseline in haematology parameter was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24 and Week 52

  11. Change From Baseline in the Haematology Parameter- Hemoglobin at Week 24 and Week 52

    Change from Baseline in hemoglobin was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24 and Week 52

  12. Change From Baseline in the Hematology Parameter- Hematocrit at Week 24 and Week 52

    Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24 and Week 52

  13. Change From Baseline in Haematology Parameter- Mean Corposcular Hemoglobin (MCH) at Week 24 and Week 52

    Change from Baseline in MCH was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24 and Week 52

  14. Change From Baseline in Haematology Parameter- Mean Corposcular Volume (MCV) at Week 24 and Week 52

    Change from Baseline in MCV was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24 and Week 52

  15. Change From Baseline in Haematology Parameter- Red Blood Cell (RBC) at Week 24 and Week 52

    Change from Baseline in RBC was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24 and Week 52

  16. Change From Baseline in Clinical Chemistry Parameter- Albumin at Week 24 and Week 52

    Change from Baseline in albumin was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24 and Week 52

  17. Change From Baseline in Clinical Chemistry Parameter- ALP, ALT, AST at Week 24 and Week 52

    Clinical chemistry parameter included alkaline phosphatase (ALP), alanine amino Transferase (ALT) and aspartate amino transferase (AST). Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24 and Week 52

  18. Change From Baseline in Clinical Chemistry Parameter- Direct Bilirubin, Total Bilirubin and Creatinine at Week 24 and Week 52

    Clinical chemistry parameters included direct bilirubin (DB), total bilirubin (TB) and creatinine (C). Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24 and Week 52

  19. Change From Baseline in Clinical Chemistry Parameter- Ca, CO2/Bicar, Gl, K, Na, PhI, U/BUN at Week 24 and Week 52

    Clinical chemistry parameters included calcium (Ca), carbon dioxide content/bicarbonate (CO2/Bicar), glucose (Gl), potassium (K), sodium (Na), phosphorus inorganic (PhI), urea/blood urine nitrogen (U/BUN). Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24 and Week 52

  20. Change From Baseline in Clinical Chemistry Parameter- Glomerular Filtration Rate (GFR) at Week 24 and Week 52

    Change from Baseline in GFR was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24 and Week 52

  21. Change From Baseline in Immunoglobulin A (IgA), Immunoglobulin G (IgG) and Immunoglobulin M (IgM) at Week 24 and Week 52

    Change from Baseline in immunoglobulins IgA, IgG and IgM was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24 and Week 52

Secondary outcomes

  1. Median Percent Change From Baseline in Memory B Cell Count at Week 24 and Week 52

    Memory B cells are B cell sub-type that are formed within germinal centres following primary infection and are important in generating an accelerated and more robust antibody-mediated immune response in the case of re-infection. Memory B cell count included CD20+CD27+ cells/mm\^3. Baseline value used in the analysis was of Day 0 (Day of transplant). Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Percent change from Baseline in Memory B cell count was calculated as the value at Week 24 and Week 52 minus the value at Baseline multiplied by 100. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Median Difference and 95% confidence interval of difference obtained using the Hodges-Lehmann method.

    Time frame: Baseline, Week 24 and Week 52

  2. Activated Memory B Cells Count at Week 24 and Week 52

    Activated memory B cell-CD95% count is CD19+CD27+CD95 conc-cells/mL. Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Week 24 and Week 52

  3. Activated Memory B Cells Percentage at Week 24 and Week 52

    Activated memory B cell-CD95% percentage is CD19+CD27+CD95+ (%CD19/CD27). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Week 24 and Week 52

  4. Transitional B Cells Count at Week 24 and Week 52

    Transitional B cell count (Newell) is CD19+CD24b+CD38b+IgD+ (Conc-cells/mL). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Week 24 and Week 52

  5. Transitional B Cells Percentage at Week 24 and Week 52

    Transitional B cell percentage (Newell) is CD19+CD24b+CD38b+IgD+ (%CD19+). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Week 24 and Week 52

  6. Activated T Cell Count at Week 24 and Week 52

    A T cell is a type of lymphocyte that plays a central role in cell-mediated immunity. Activated T cell count Codarri is CD4+ CD25hi CD45RA- IL 7Rhi (Conc-cells/mL). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Week 24 and Week 52

  7. Activated T Cell Percentage at Week 24 and Week 52

    Activated T cell percentage (Codarri)= CD4+ CD25hi CD45RA- IL 7Rhi (% of CD4+). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Week 24 and Week 52

  8. Regulatory T Cell Count at Week 24 and Week 52

    Regulatory T cell count is CD4+ CD25hi IL-7Rlo (Conc-cells/mL). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Week 24 and Week 52

  9. Regulatory T Cell (%CD4) at Week 24 and Week 52

    Regulatory T cell (%CD4) = CD4+ CD25hi IL-7Rlo (% of CD4+). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Week 24 and Week 52

  10. Mean Activated: Regulatory T Cell Ratio at Week 24 and Week 52

    Activated: regulatory T cell ratio is Activated T cell CD4+CD25hi CD45RA IL 7Rhi (absolute number)/ Regulatory T cell CD4+CD25hi CD45RA IL 7Rlo (absolute number). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Week 24 and Week 52

  11. Proportion of Participants With Episodes of Acute Rejection at Week 24 and Week 52

    The endpoint diagnosis was made by a proven biopsy result. Number of rejections only counted once per participant. The proportion of participants with episodes of acute rejection was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Week 24 and Week 52

  12. Mean Serum Creatinine at Week 24 and Week 52

    Adjusted mean difference for serum creatinine values (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction, at Week 24 and Week 52. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Week 24 and Week 52

  13. Mean eGFR at Week 24 and Week 52

    The estimated glomerular filtration rate (eGFR) were calculated by the abbreviated Modification of Diet in Renal Disease (MDRD) equation. Adjusted mean difference(treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction at Week 24 and Week 52. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the indicated time points were analyzed (represented by n= X, X in the category titles).

    Time frame: Week 24 and Week 52

  14. Mean Prednisolone Use at Week 24

    Adjusted mean difference (treatment-placebo) for Prednisolone use and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction at Week 24. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments Only those participants available at indicated timepoints were analyzed (represented by n=X, X in the category titles).

    Time frame: Week 24

07

Results

Posted Apr 25, 2017

Participant flow

A total of 30 renal transplant recipients were enrolled, of which 28 were randomized and 25 were transplanted.

Participant flow — Overall Study
MilestonePlaceboBelimumab 10mg/kg
Started1312
Completed119
Not completed23
Withdrew: Adverse event12
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryChange From Baseline in naïve B Cells From Baseline to Week 24

Naive B cell is cell that is not exposed to antigen. Naïve B cell count is CD20+CD27 concentration of cells (conc-cell)/cubic millimeter (cumm). Change from Baseline in naïve B cells was calculated as the value at Week 24 minus the value at Baseline. MITT Population consisted of all participants randomized to treatment, who have had taken at least one dose of study. Participants analyzed included those who had data at Week 24 for naïve B cells count (MITT Population). Baseline value used in the analysis was of Day 0 (Day of transplant). Adjusted mean differences (treatment-placebo) and 95% confidence intervals for differences were obtained from mixed-models repeated-measures (MMRM) model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · cells/mm^3
Change From Baseline in naïve B Cells From Baseline to Week 24
cells/mm^3PlaceboBelimumab 10mg/kg
Change From Baseline in naïve B Cells From Baseline to Week 244.0 ± 25.55-30.4 ± 27.50
Statistical analysis
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -34.4 · 95% CI -109.5 to 40.7
PrimaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)

Number of participants with AEs, SAEs and AESI are summarized. The On-treatment (OT) phase started on the day and time of receiving the start of the first infusion and ended on the last dose date plus 28 days. The Post-treatment (PT) phase started 29 days after day of last dose up to 1 year. An AE is any untoward medical occurrence, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that at any dose results in, death, is life threatening, Requires hospitalization or prolongation of existing hospitalization, Results in disability/incapacity, Is a congenital anomaly/birth defect or event that but may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed. AESI included malignant neoplasms, infusion/anaphylaxis/hypersensitivity reactions, all infections, depression/suicide/self-injury, deaths.

Time frame:
Up to 1 year
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)
ParticipantsPlaceboBelimumab 10mg/kg
OT AEs1011
PT AEs910
OT SAEs75
PT SAEs22
Malignant neoplasms00
Post-Infusion Systemic Reactions01
All Infections67
Depression/suicide/self-injury00
Deaths10
PrimaryNumber of Incidence of All Infections and Serious Infections

All infections included: 1. Opportunistic infections per-clinical assessment, 2. Herpes Zoster, a. Recurrent, b. Disseminated, 3. Sepsis. Opportunistic infections were identified using list of preferred terms as per Medical Dictionary for Regulatory Activities (MedDRA) version 18.1. Any events falling under these preferred terms were adjudicated to determine if criteria was met for an opportunistic infection.

Time frame:
Up to 1 year
Reported as:
Number · Infections
Number of Incidence of All Infections and Serious Infections
InfectionsPlaceboBelimumab 10mg/kg
All Infections87
Serious Infections21
All Opportunistic Infections75
Serious Opportunistic Infections10
All Herpes Zoster01
Serious Herpes Zoster00
Sepsis32
Serious Sepsis21
PrimaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 24 and Week 52

Change from Baseline in SBP and DBP were assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value at Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Mean · millimeter of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 24 and Week 52
millimeter of mercury (mmHg)PlaceboBelimumab 10mg/kg
DBP Week 24; n=9, 7-4.444 ± 14.32757.286 ± 13.8289
DBP Week 52; n=11, 10-6.545 ± 13.96684.200 ± 8.5479
SBP Week 24; n=9, 72.000 ± 26.096010.000 ± 35.9444
SBP Week 52; n=11, 10-2.909 ± 27.20463.300 ± 27.9008
PrimaryChange From Baseline in Heart Rate From Baseline at Week 24 and Week 52

Change from Baseline in heart rate was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value at Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Mean · Beats per minute (BPM)
Change From Baseline in Heart Rate From Baseline at Week 24 and Week 52
Beats per minute (BPM)PlaceboBelimumab 10mg/kg
Week 24; n=8, 65.125 ± 16.89831.500 ± 13.6345
Week 52; n=11, 92.000 ± 11.5065-2.444 ± 15.4200
PrimaryChange From Baseline in Body Temperature From Baseline at Week 24 and Week 52

Change from Baseline in body temperature was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value at Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Mean · Degree Centigrade
Change From Baseline in Body Temperature From Baseline at Week 24 and Week 52
Degree CentigradePlaceboBelimumab 10mg/kg
Week 24; n=8, 60.025 ± 0.7025-0.233 ± 0.5007
Week 52; n=11, 10-0.045 ± 0.48030.030 ± 0.5417
PrimaryNumber of Participants Outside the Normal Range (NR) for SBP and DBP at Week 24 and Week 52

Number of participants outside the normal range (NR) for SBP and DBP was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Number of participants outside the normal range are summarized by less than (\<) normal range and greater than (\>) normal range categories at Week 24 and Week 52. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Week 24 and Week 52
Reported as:
Number · Participants
Number of Participants Outside the Normal Range (NR) for SBP and DBP at Week 24 and Week 52
ParticipantsPlaceboBelimumab 10mg/kg
DBP, > NR, Week 24; n=9, 711
DBP, < NR, Week 24; n=9, 712
DBP, > NR, Week 52; n=11, 1030
DBP, < NR, Week 52; n=11, 1021
SBP, > NR, Week 24; n=9, 753
SBP, < NR, Week 24; n=9, 700
SBP, > NR, Week 52; n=11, 1054
SBP, < NR, Week 52; n=11, 1001
PrimaryNumber of Participants Outside the Normal Range (NR) for Heart Rate at Week 24 and Week 52

Number of participants outside the normal range (NR) for heart rate was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Number of participants outside the normal range are summarized by less than (\<) normal range and greater than (\>) normal range categories at Week 24 and Week 52. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Week 24 and Week 52
Reported as:
Number · Participants
Number of Participants Outside the Normal Range (NR) for Heart Rate at Week 24 and Week 52
ParticipantsPlaceboBelimumab 10mg/kg
> NR Week 24; n=8, 610
< NR Week 24; n=8, 620
> NR Week 52; n=11, 900
< NR Week 52; n=11, 911
PrimaryNumber of Participants Outside the Normal Range (NR) for Body Temperature at Week 24 and Week 52

Number of participants outside the normal range (NR) for body temperature was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Number of participants outside the normal range are summarized by less than (\<) normal range and greater than (\>) normal range categories at Week 24 and Week 52. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Week 24 and Week 52
Reported as:
Number · Participants
Number of Participants Outside the Normal Range (NR) for Body Temperature at Week 24 and Week 52
ParticipantsPlaceboBelimumab 10mg/kg
> NR Week 24; n=8, 600
< NR Week 24; n=8, 634
> NR Week 52; n=11, 1000
< NR Week 52; n=11, 1052
PrimaryChange From Baseline in the Indicated Hematology Parameters at Week 24 and Week 52

Hematology parameters included: basophils (B), eosinophils (E), lymphocytes (L), monocytes (M), total neutrophils (N), platelet count (PC) and white blood cells (WBC). Change from Baseline in haematology parameter was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Mean · Gills/Liter (GI/L)
Change From Baseline in the Indicated Hematology Parameters at Week 24 and Week 52
Gills/Liter (GI/L)PlaceboBelimumab 10mg/kg
B Week 24; n=9, 6-0.001 ± 0.0215-0.015 ± 0.0207
B Week 52; n=10, 100.033 ± 0.1024-0.005 ± 0.0357
E Week 24; n=9, 6-0.531 ± 1.0250-0.140 ± 0.1274
E Week 52; n=10, 10-0.392 ± 0.8048-0.127 ± 0.1489
L Week 24; n=9, 6-0.218 ± 0.6457-0.347 ± 0.3467
L Week 52; n=10, 100.085 ± 0.5841-0.245 ± 0.3357
M Week 24; n=9, 6-0.097 ± 0.2231-0.365 ± 0.3509
M Week 52; n=10, 100.001 ± 0.1799-0.111 ± 0.3892
TN Week 24; n=9, 60.946 ± 2.6602-0.083 ± 2.4752
TN Week 52; n=10, 101.657 ± 3.5533-0.606 ± 3.3406
PC Week 24; n=9, 615.9 ± 59.647.3 ± 40.35
PC Week 52; n=11, 1018.1 ± 55.81-10.0 ± 54.14
WBC Week 24; n=9, 60.10 ± 3.483-0.95 ± 2.868
WBC Week 52; n=11, 101.47 ± 3.572-1.11 ± 3.557
PrimaryChange From Baseline in the Haematology Parameter- Hemoglobin at Week 24 and Week 52

Change from Baseline in hemoglobin was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Mean · Grams per Liter (G/L)
Change From Baseline in the Haematology Parameter- Hemoglobin at Week 24 and Week 52
Grams per Liter (G/L)PlaceboBelimumab 10mg/kg
Week 24; n=9, 65.4 ± 24.8413.2 ± 28.90
Week 52; n=11, 1012.6 ± 22.696.3 ± 23.48
PrimaryChange From Baseline in the Hematology Parameter- Hematocrit at Week 24 and Week 52

Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Mean · Percentage of blood
Change From Baseline in the Hematology Parameter- Hematocrit at Week 24 and Week 52
Percentage of bloodPlaceboBelimumab 10mg/kg
Week 24; n=9, 60.0216 ± 0.066250.0477 ± 0.09540
Week 52; n=11, 100.0434 ± 0.068130.0238 ± 0.07045
PrimaryChange From Baseline in Haematology Parameter- Mean Corposcular Hemoglobin (MCH) at Week 24 and Week 52

Change from Baseline in MCH was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Mean · Picogram (pg)
Change From Baseline in Haematology Parameter- Mean Corposcular Hemoglobin (MCH) at Week 24 and Week 52
Picogram (pg)PlaceboBelimumab 10mg/kg
Week 24; n=8, 6-0.79 ± 2.173-1.37 ± 2.683
Week 52; n=10, 10-1.59 ± 1.516-1.93 ± 2.743
PrimaryChange From Baseline in Haematology Parameter- Mean Corposcular Volume (MCV) at Week 24 and Week 52

Change from Baseline in MCV was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Mean · Femtoliter (FL)
Change From Baseline in Haematology Parameter- Mean Corposcular Volume (MCV) at Week 24 and Week 52
Femtoliter (FL)PlaceboBelimumab 10mg/kg
Week 24; n=9, 6-1.73 ± 6.430-2.55 ± 8.198
Week 52; n=11, 10-3.58 ± 4.340-4.61 ± 7.041
PrimaryChange From Baseline in Haematology Parameter- Red Blood Cell (RBC) at Week 24 and Week 52

Change from Baseline in RBC was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Mean · Tera (TI)/L
Change From Baseline in Haematology Parameter- Red Blood Cell (RBC) at Week 24 and Week 52
Tera (TI)/LPlaceboBelimumab 10mg/kg
Week 24; n=9, 60.298 ± 0.67160.645 ± 0.8097
Week 52; n=11, 100.635 ± 0.70640.468 ± 0.5884
PrimaryChange From Baseline in Clinical Chemistry Parameter- Albumin at Week 24 and Week 52

Change from Baseline in albumin was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Mean · G/L
Change From Baseline in Clinical Chemistry Parameter- Albumin at Week 24 and Week 52
G/LPlaceboBelimumab 10mg/kg
Week 24; n=9, 74.1 ± 2.622.9 ± 4.91
Week 52; n=10, 102.9 ± 3.001.8 ± 4.98
PrimaryChange From Baseline in Clinical Chemistry Parameter- ALP, ALT, AST at Week 24 and Week 52

Clinical chemistry parameter included alkaline phosphatase (ALP), alanine amino Transferase (ALT) and aspartate amino transferase (AST). Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Mean · International Unit (IU)/L
Change From Baseline in Clinical Chemistry Parameter- ALP, ALT, AST at Week 24 and Week 52
International Unit (IU)/LPlaceboBelimumab 10mg/kg
ALP Week 24; n=9, 7-16.0 ± 26.14-5.0 ± 60.03
ALP Week 52; n=10, 10-17.5 ± 35.2519.9 ± 80.63
ALT Week 24; n=9, 71.0 ± 15.865.1 ± 7.56
ALT Week 52; n=10, 10-2.5 ± 11.162.1 ± 5.80
AST Week 24; n=6, 33.2 ± 7.917.3 ± 4.04
AST Week 52; n=7, 43.3 ± 5.689.3 ± 3.86
PrimaryChange From Baseline in Clinical Chemistry Parameter- Direct Bilirubin, Total Bilirubin and Creatinine at Week 24 and Week 52

Clinical chemistry parameters included direct bilirubin (DB), total bilirubin (TB) and creatinine (C). Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Mean · Micromole per Liter (umol/L)
Change From Baseline in Clinical Chemistry Parameter- Direct Bilirubin, Total Bilirubin and Creatinine at Week 24 and Week 52
Micromole per Liter (umol/L)PlaceboBelimumab 10mg/kg
DB Week 24; n=8, 30.6 ± 1.51-0.7 ± 3.06
DB Week 52; n=9, 50.9 ± 1.540.2 ± 1.30
TB Week 24; n=9, 73.0 ± 6.502.7 ± 5.22
TB Week 52; n=10, 102.9 ± 5.262.9 ± 3.38
C Week 24; n=9, 7-471.1 ± 317.54-571.3 ± 183.53
C Week 52; n=10, 10-468.4 ± 310.54-609.8 ± 271.89
PrimaryChange From Baseline in Clinical Chemistry Parameter- Ca, CO2/Bicar, Gl, K, Na, PhI, U/BUN at Week 24 and Week 52

Clinical chemistry parameters included calcium (Ca), carbon dioxide content/bicarbonate (CO2/Bicar), glucose (Gl), potassium (K), sodium (Na), phosphorus inorganic (PhI), urea/blood urine nitrogen (U/BUN). Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Mean · Millimole (MMOL)/L
Change From Baseline in Clinical Chemistry Parameter- Ca, CO2/Bicar, Gl, K, Na, PhI, U/BUN at Week 24 and Week 52
Millimole (MMOL)/LPlaceboBelimumab 10mg/kg
Ca Week 24; n=9, 70.116 ± 0.13440.167 ± 0.1942
Ca Week 52; n=10, 90.116 ± 0.10130.128 ± 0.1386
CO2/Bicar Week 24; n=7, 6-3.73 ± 5.9511.70 ± 3.449
CO2/Bicar Week 52; n=8, 9-2.68 ± 5.1420.77 ± 3.588
Gl Week 24; n=5, 50.20 ± 3.093-0.04 ± 2.003
Gl Week 52; n=5, 8-0.32 ± 2.4831.79 ± 4.107
K Week 24; n=9, 70.06 ± 0.723-0.63 ± 0.923
K Week 52; n=10, 10-0.02 ± 0.535-0.44 ± 0.877
Na Week 24; n=9, 7-0.6 ± 4.035.9 ± 5.01
Na Week 52; n=10, 10-0.7 ± 3.712.2 ± 4.71
PhI Week 24; n=8, 7-0.225 ± 0.3843-0.913 ± 0.5862
PhI Week 52; n=9, 9-0.227 ± 0.4234-0.726 ± 0.5453
U/BUN Week 24; n=9, 6-5.91 ± 12.164-9.47 ± 9.128
U/BUN Week 52; n=10, 9-8.13 ± 14.967-9.01 ± 7.323
PrimaryChange From Baseline in Clinical Chemistry Parameter- Glomerular Filtration Rate (GFR) at Week 24 and Week 52

Change from Baseline in GFR was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Mean · milliliter (mL)/Minute (min)
Change From Baseline in Clinical Chemistry Parameter- Glomerular Filtration Rate (GFR) at Week 24 and Week 52
milliliter (mL)/Minute (min)PlaceboBelimumab 10mg/kg
Week 24; n=9, 742.80 ± 23.60444.36 ± 10.731
Week 52; n=10, 1042.33 ± 29.14053.75 ± 15.176
PrimaryChange From Baseline in Immunoglobulin A (IgA), Immunoglobulin G (IgG) and Immunoglobulin M (IgM) at Week 24 and Week 52

Change from Baseline in immunoglobulins IgA, IgG and IgM was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Mean · G/L
Change From Baseline in Immunoglobulin A (IgA), Immunoglobulin G (IgG) and Immunoglobulin M (IgM) at Week 24 and Week 52
G/LPlaceboBelimumab 10mg/kg
IgA Week 24; n=2, 3-0.500 ± 0.2828-0.433 ± 0.6429
IgA Week 52; n=2, 3-0.300 ± 0.0000-0.500 ± 0.5292
IgG Week 24; n=6, 6-1.02 ± 1.184-2.40 ± 1.731
IgG Week 52; n=10, 90.78 ± 3.595-2.13 ± 1.702
IgM Week 24; n=2, 3-0.100 ± 0.0000-0.133 ± 0.3512
IgM Week 52; n=2, 30.0000 ± 0.0000-0.333 ± 0.4933
SecondaryMedian Percent Change From Baseline in Memory B Cell Count at Week 24 and Week 52

Memory B cells are B cell sub-type that are formed within germinal centres following primary infection and are important in generating an accelerated and more robust antibody-mediated immune response in the case of re-infection. Memory B cell count included CD20+CD27+ cells/mm\^3. Baseline value used in the analysis was of Day 0 (Day of transplant). Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Percent change from Baseline in Memory B cell count was calculated as the value at Week 24 and Week 52 minus the value at Baseline multiplied by 100. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Median Difference and 95% confidence interval of difference obtained using the Hodges-Lehmann method.

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Median · Percent change
Median Percent Change From Baseline in Memory B Cell Count at Week 24 and Week 52
Percent changePlaceboBelimumab 10mg/kg
Week 24; n=9, 7-12.5 (-88 to 320)177.8 (40 to 800)
Week 52; n=10, 72.4 (-67 to 340)-33.3 (-80 to 44)
Statistical analysis
  • Placebo vs Belimumab 10mg/kg · Median difference (final values): 204.35 · 95% CI 90.00 to 550.00Week 24 comparison
  • Placebo vs Belimumab 10mg/kg · Median difference (final values): -33.06 · 95% CI -169.84 to 25.00Week 52 comparison
SecondaryActivated Memory B Cells Count at Week 24 and Week 52

Activated memory B cell-CD95% count is CD19+CD27+CD95 conc-cells/mL. Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Week 24 and Week 52
Reported as:
Least squares mean · cells/mL
Activated Memory B Cells Count at Week 24 and Week 52
cells/mLPlaceboBelimumab 10mg/kg
Week 24; n=9, 737157.2 ± 16664.4238389.6 ± 18682.83
Week 52; n=10, 824220.8 ± 15744.1711092.5 ± 17711.36
Statistical analysis
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): 1232.40 · 95% CI -50457.0 to 52921.8Week 24 comparison
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -13128.35 · 95% CI -61868.9 to 35612.2Week 52 comparison
SecondaryActivated Memory B Cells Percentage at Week 24 and Week 52

Activated memory B cell-CD95% percentage is CD19+CD27+CD95+ (%CD19/CD27). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Week 24 and Week 52
Reported as:
Least squares mean · Percentage of activated memory B cells
Activated Memory B Cells Percentage at Week 24 and Week 52
Percentage of activated memory B cellsPlaceboBelimumab 10mg/kg
Week 24; n=9, 732.8 ± 5.9419.0 ± 6.06
Week 52; n=11, 1032.0 ± 5.0738.8 ± 5.48
Statistical analysis
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -13.8 · 95% CI -31.3 to 3.7Week 24 comparison
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): 6.8 · 95% CI -8.6 to 22.2Week 52 comparison
SecondaryTransitional B Cells Count at Week 24 and Week 52

Transitional B cell count (Newell) is CD19+CD24b+CD38b+IgD+ (Conc-cells/mL). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Week 24 and Week 52
Reported as:
Least squares mean · cells/mL
Transitional B Cells Count at Week 24 and Week 52
cells/mLPlaceboBelimumab 10mg/kg
Week 24; n=9, 75470 ± 2910.92679 ± 3518.4
Week 52; n=10, 87110 ± 2836.76652 ± 3291.5
Statistical analysis
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -2791 · 95% CI -12105 to 6524Week 24 comparison
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -458 · 95% CI -9487 to 8572Week 52 comparison
SecondaryTransitional B Cells Percentage at Week 24 and Week 52

Transitional B cell percentage (Newell) is CD19+CD24b+CD38b+IgD+ (%CD19+). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Week 24 and Week 52
Reported as:
Least squares mean · Percentage of transitional B cells
Transitional B Cells Percentage at Week 24 and Week 52
Percentage of transitional B cellsPlaceboBelimumab 10mg/kg
Week 24; n=9, 72.43 ± 0.7761.14 ± 0.869
Week 52; n=11, 102.61 ± 0.7133.41 ± 0.731
Statistical analysis
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -1.29 · 95% CI -3.59 to 1.01Week 24 comparison
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): 0.79 · 95% CI -1.24 to 2.82Week 52 comparison
SecondaryActivated T Cell Count at Week 24 and Week 52

A T cell is a type of lymphocyte that plays a central role in cell-mediated immunity. Activated T cell count Codarri is CD4+ CD25hi CD45RA- IL 7Rhi (Conc-cells/mL). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Week 24 and Week 52
Reported as:
Least squares mean · cells/mL
Activated T Cell Count at Week 24 and Week 52
cells/mLPlaceboBelimumab 10mg/kg
Week 24; n=9, 6109279.5 ± 22998.0278952.7 ± 26155.19
Week 52; n=10, 7122304.7 ± 21898.2475349.4 ± 24313.62
Statistical analysis
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -30326.9 · 95% CI -100559.1 to 39905.3Week 24 comparison
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -46955.3 · 95% CI -113218.9 to 19308.3Week 52 comparison
SecondaryActivated T Cell Percentage at Week 24 and Week 52

Activated T cell percentage (Codarri)= CD4+ CD25hi CD45RA- IL 7Rhi (% of CD4+). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Week 24 and Week 52
Reported as:
Least squares mean · Percentage of activated T cell
Activated T Cell Percentage at Week 24 and Week 52
Percentage of activated T cellPlaceboBelimumab 10mg/kg
Week 24; n=9, 617.0 ± 2.2914.0 ± 2.58
Week 52; n=10, 715.2 ± 2.1514.7 ± 2.33
Statistical analysis
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -3.0 · 95% CI -10.1 to 4.2Week 24 comparison
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -0.4 · 95% CI -7.2 to 6.3Week 52 comparison
SecondaryRegulatory T Cell Count at Week 24 and Week 52

Regulatory T cell count is CD4+ CD25hi IL-7Rlo (Conc-cells/mL). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Week 24 and Week 52
Reported as:
Least squares mean · cells/mL
Regulatory T Cell Count at Week 24 and Week 52
cells/mLPlaceboBelimumab 10mg/kg
Week 24; n= 9, 723586.2 ± 8427.7724234.5 ± 9238.41
Week 52; n= 10, 833038.7 ± 7676.9927419.8 ± 9093.84
Statistical analysis
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): 648.3 · 95% CI -24661.1 to 25957.7Week 24 comparison
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -5618.9 · 95% CI -29994.8 to 18757.0Week 52 comparison
SecondaryRegulatory T Cell (%CD4) at Week 24 and Week 52

Regulatory T cell (%CD4) = CD4+ CD25hi IL-7Rlo (% of CD4+). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Week 24 and Week 52
Reported as:
Least squares mean · Percentage of Regulatory T cell
Regulatory T Cell (%CD4) at Week 24 and Week 52
Percentage of Regulatory T cellPlaceboBelimumab 10mg/kg
Week 24; n= 9, 74.4 ± 1.124.6 ± 1.25
Week 52; n= 11, 105.0 ± 1.014.4 ± 1.04
Statistical analysis
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): 0.1 · 95% CI -3.2 to 3.5Week 24 comparison
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -0.6 · 95% CI -3.5 to 2.3Week 52 comparison
SecondaryMean Activated: Regulatory T Cell Ratio at Week 24 and Week 52

Activated: regulatory T cell ratio is Activated T cell CD4+CD25hi CD45RA IL 7Rhi (absolute number)/ Regulatory T cell CD4+CD25hi CD45RA IL 7Rlo (absolute number). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Week 24 and Week 52
Reported as:
Least squares mean · Ratio
Mean Activated: Regulatory T Cell Ratio at Week 24 and Week 52
RatioPlaceboBelimumab 10mg/kg
Week 24; n= 9, 64.88 ± 0.8323.33 ± 0.915
Week 52; n= 10, 74.62 ± 0.7793.61 ± 0.942
Statistical analysis
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -1.54 · 95% CI -4.07 to 0.98Week 24 comparison
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -1.01 · 95% CI -3.68 to 1.67Week 52 comparison
SecondaryProportion of Participants With Episodes of Acute Rejection at Week 24 and Week 52

The endpoint diagnosis was made by a proven biopsy result. Number of rejections only counted once per participant. The proportion of participants with episodes of acute rejection was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Week 24 and Week 52
Reported as:
Number · Proportion of participants
Proportion of Participants With Episodes of Acute Rejection at Week 24 and Week 52
Proportion of participantsPlaceboBelimumab 10mg/kg
Week 24; n=5, 60.40.33
Week 52; n=5, 60.60.33
Statistical analysis
  • Placebo vs Belimumab 10mg/kg · Difference in proportion: -0.067 · 95% CI -0.638 to 0.505Week 24 comparison
  • Placebo vs Belimumab 10mg/kg · Difference in proportion: -0.267 · 95% CI -0.838 to 0.305Week 52 comparison
SecondaryMean Serum Creatinine at Week 24 and Week 52

Adjusted mean difference for serum creatinine values (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction, at Week 24 and Week 52. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Week 24 and Week 52
Reported as:
Least squares mean · micromole/L
Mean Serum Creatinine at Week 24 and Week 52
micromole/LPlaceboBelimumab 10mg/kg
Week 24; n=9, 7115.1 ± 35.24112.3 ± 38.20
Week 52; n= 10, 10135.4 ± 33.50122.6 ± 33.37
Statistical analysis
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -2.8 · 95% CI -105.9 to 100.3Week 24 comparison
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -12.9 · 95% CI -107.1 to 81.4Week 52 comparison
SecondaryMean eGFR at Week 24 and Week 52

The estimated glomerular filtration rate (eGFR) were calculated by the abbreviated Modification of Diet in Renal Disease (MDRD) equation. Adjusted mean difference(treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction at Week 24 and Week 52. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the indicated time points were analyzed (represented by n= X, X in the category titles).

Time frame:
Week 24 and Week 52
Reported as:
Least squares mean · mL/minute/1.73 square meter (m^2)
Mean eGFR at Week 24 and Week 52
mL/minute/1.73 square meter (m^2)PlaceboBelimumab 10mg/kg
Week 24; n=9, 762.25 ± 6.11949.33 ± 6.897
Week 52; n= 10, 1058.99 ± 5.73256.29 ± 5.765
Statistical analysis
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -12.92 · 95% CI -31.56 to 5.71Week 24 comparison
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -2.70 · 95% CI -19.11 to 13.72Week 52 comparison
SecondaryMean Prednisolone Use at Week 24

Adjusted mean difference (treatment-placebo) for Prednisolone use and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction at Week 24. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments Only those participants available at indicated timepoints were analyzed (represented by n=X, X in the category titles).

Time frame:
Week 24
Reported as:
Least squares mean · mg/day
Mean Prednisolone Use at Week 24
mg/dayPlaceboBelimumab 10mg/kg
Mean Prednisolone Use at Week 245.71 ± 1.4385.27 ± 1.713
Statistical analysis
  • Placebo vs Belimumab 10mg/kg · Mean difference (final values): -0.44 · 95% CI -4.84 to 3.96

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until follow-up (up to 52 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—7/13 (53.8%)9/13 (69.2%)
Belimumab 10mg/kg—5/12 (41.7%)9/12 (75%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPlaceboBelimumab 10mg/kg
Blood creatinine increasedInvestigations0/131/12
Clostridium difficile colitisInfections and infestations0/131/12
ColitisGastrointestinal disorders0/131/12
DehydrationMetabolism and nutrition disorders0/131/12
DeliriumPsychiatric disorders0/131/12
DiarrhoeaGastrointestinal disorders0/131/12
Focal segmental glomerulosclerosisRenal and urinary disorders0/131/12
LymphoceleVascular disorders0/131/12
PneumoniaInfections and infestations0/131/12
Transplant rejectionImmune system disorders0/131/12
Most frequent other events
Showing 10 of 50
Most frequent other events
EventPlaceboBelimumab 10mg/kg
DiarrhoeaGastrointestinal disorders3/135/12
LeukopeniaBlood and lymphatic system disorders4/134/12
Urinary tract infectionInfections and infestations2/134/12
AnaemiaBlood and lymphatic system disorders3/132/12
DyspepsiaGastrointestinal disorders2/132/12
Alanine aminotransferase increasedInvestigations1/132/12
Lower respiratory tract infectionInfections and infestations1/132/12
DizzinessNervous system disorders0/132/12
VomitingGastrointestinal disorders0/132/12
NasopharyngitisInfections and infestations2/131/12

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboBelimumab 10mg/kgTotal
Mean51.0 ± 14.0254.3 ± 11.0252.6 ± 12.52
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBelimumab 10mg/kgTotal
Female4711
Male9514
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBelimumab 10mg/kgTotal
White/Caucasian121123
Asian112
08

Study locations

2 sites
  • GSK Investigational Site
    Cambridge, CB2 0QQ, United Kingdom
  • GSK Investigational Site
    London, SE1 9RT, United Kingdom
09

References and documents

Publications

  • Banham GD, Flint SM, Torpey N, Lyons PA, Shanahan DN, Gibson A, Watson CJE, O'Sullivan AM, Chadwick JA, Foster KE, Jones RB, Devey LR, Richards A, Erwig LP, Savage CO, Smith KGC, Henderson RB, Clatworthy MR. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial. Lancet. 2018 Jun 30;391(10140):2619-2630. doi: 10.1016/S0140-6736(18)30984-X. Epub 2018 Jun 14. PubMed 29910042 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2012
First posted
Feb 22, 2012
Start
Sep 2013
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Results first posted
Apr 25, 2017
Last update
Apr 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01536379
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 22, 2012
Start date
Sep 2013
Primary completion
Feb 2016
Completion
Feb 2016
Results posted
Apr 25, 2017
Last update
Apr 25, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion